Click for best price
Constrained Peptide Drugs Market Size, Share 2022
This report contains market size and forecasts of Constrained Peptide Drugs in Global, including the following market information:
Global Constrained Peptide Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Constrained Peptide Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cyclic Peptides Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Constrained Peptide Drugs include Aileron Therapeutics, Inc, Bicycle Therapeutics, PLC, Polyphor Limited, Protagonist Therapeutics, Inc, Santhera Pharmaceuticals Holding, Union Chimique Belge S.A. (UCB), Pepscan Therapeutics B.V., Pepticom Ltd. and PeptiDream, Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Constrained Peptide Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Constrained Peptide Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Constrained Peptide Drugs Market Segment Percentages, by Type, 2021 (%)
Cyclic Peptides
Disulfide-Rich Peptides (DRPs)
Global Constrained Peptide Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Constrained Peptide Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital
Institute of Biology
Others
Global Constrained Peptide Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Constrained Peptide Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Constrained Peptide Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Constrained Peptide Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Aileron Therapeutics, Inc
Bicycle Therapeutics, PLC
Polyphor Limited
Protagonist Therapeutics, Inc
Santhera Pharmaceuticals Holding
Union Chimique Belge S.A. (UCB)
Pepscan Therapeutics B.V.
Pepticom Ltd.
PeptiDream, Inc.
CPC Scientific Inc.
Creative Peptides
Bio-Synthesis Inc
| Report Attributes |
Report Details |
| Report Title |
Constrained Peptide Drugs Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
63 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Constrained Peptide Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Constrained Peptide Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Constrained Peptide Drugs Overall Market Size
2.1 Global Constrained Peptide Drugs Market Size: 2021 VS 2028
2.2 Global Constrained Peptide Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Constrained Peptide Drugs Players in Global Market
3.2 Top Global Constrained Peptide Drugs Companies Ranked by Revenue
3.3 Global Constrained Peptide Drugs Revenue by Companies
3.4 Top 3 and Top 5 Constrained Peptide Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Constrained Peptide Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Constrained Peptide Drugs Players in Global Market
3.6.1 List of Global Tier 1 Constrained Peptide Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Constrained Peptide Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Constrained Peptide Drugs Market Size Markets, 2021 & 2028
4.1.2 Cyclic Peptides
4.1.3 Disulfide-Rich Peptides (DRPs)
4.2 By Type - Global Constrained Peptide Drugs Revenue & Forecasts
4.2.1 By Type - Global Constrained Peptide Drugs Revenue, 2017-2022
4.2.2 By Type - Global Constrained Peptide Drugs Revenue, 2023-2028
4.2.3 By Type - Global Constrained Peptide Drugs Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Constrained Peptide Drugs Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Institute of Biology
5.1.4 Others
5.2 By Application - Global Constrained Peptide Drugs Revenue & Forecasts
5.2.1 By Application - Global Constrained Peptide Drugs Revenue, 2017-2022
5.2.2 By Application - Global Constrained Peptide Drugs Revenue, 2023-2028
5.2.3 By Application - Global Constrained Peptide Drugs Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Constrained Peptide Drugs Market Size, 2021 & 2028
6.2 By Region - Global Constrained Peptide Drugs Revenue & Forecasts
6.2.1 By Region - Global Constrained Peptide Drugs Revenue, 2017-2022
6.2.2 By Region - Global Constrained Peptide Drugs Revenue, 2023-2028
6.2.3 By Region - Global Constrained Peptide Drugs Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Constrained Peptide Drugs Revenue, 2017-2028
6.3.2 US Constrained Peptide Drugs Market Size, 2017-2028
6.3.3 Canada Constrained Peptide Drugs Market Size, 2017-2028
6.3.4 Mexico Constrained Peptide Drugs Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Constrained Peptide Drugs Revenue, 2017-2028
6.4.2 Germany Constrained Peptide Drugs Market Size, 2017-2028
6.4.3 France Constrained Peptide Drugs Market Size, 2017-2028
6.4.4 U.K. Constrained Peptide Drugs Market Size, 2017-2028
6.4.5 Italy Constrained Peptide Drugs Market Size, 2017-2028
6.4.6 Russia Constrained Peptide Drugs Market Size, 2017-2028
6.4.7 Nordic Countries Constrained Peptide Drugs Market Size, 2017-2028
6.4.8 Benelux Constrained Peptide Drugs Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Constrained Peptide Drugs Revenue, 2017-2028
6.5.2 China Constrained Peptide Drugs Market Size, 2017-2028
6.5.3 Japan Constrained Peptide Drugs Market Size, 2017-2028
6.5.4 South Korea Constrained Peptide Drugs Market Size, 2017-2028
6.5.5 Southeast Asia Constrained Peptide Drugs Market Size, 2017-2028
6.5.6 India Constrained Peptide Drugs Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Constrained Peptide Drugs Revenue, 2017-2028
6.6.2 Brazil Constrained Peptide Drugs Market Size, 2017-2028
6.6.3 Argentina Constrained Peptide Drugs Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Constrained Peptide Drugs Revenue, 2017-2028
6.7.2 Turkey Constrained Peptide Drugs Market Size, 2017-2028
6.7.3 Israel Constrained Peptide Drugs Market Size, 2017-2028
6.7.4 Saudi Arabia Constrained Peptide Drugs Market Size, 2017-2028
6.7.5 UAE Constrained Peptide Drugs Market Size, 2017-2028
7 Players Profiles
7.1 Aileron Therapeutics, Inc
7.1.1 Aileron Therapeutics, Inc Corporate Summary
7.1.2 Aileron Therapeutics, Inc Business Overview
7.1.3 Aileron Therapeutics, Inc Constrained Peptide Drugs Major Product Offerings
7.1.4 Aileron Therapeutics, Inc Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.1.5 Aileron Therapeutics, Inc Key News
7.2 Bicycle Therapeutics, PLC
7.2.1 Bicycle Therapeutics, PLC Corporate Summary
7.2.2 Bicycle Therapeutics, PLC Business Overview
7.2.3 Bicycle Therapeutics, PLC Constrained Peptide Drugs Major Product Offerings
7.2.4 Bicycle Therapeutics, PLC Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.2.5 Bicycle Therapeutics, PLC Key News
7.3 Polyphor Limited
7.3.1 Polyphor Limited Corporate Summary
7.3.2 Polyphor Limited Business Overview
7.3.3 Polyphor Limited Constrained Peptide Drugs Major Product Offerings
7.3.4 Polyphor Limited Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.3.5 Polyphor Limited Key News
7.4 Protagonist Therapeutics, Inc
7.4.1 Protagonist Therapeutics, Inc Corporate Summary
7.4.2 Protagonist Therapeutics, Inc Business Overview
7.4.3 Protagonist Therapeutics, Inc Constrained Peptide Drugs Major Product Offerings
7.4.4 Protagonist Therapeutics, Inc Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.4.5 Protagonist Therapeutics, Inc Key News
7.5 Santhera Pharmaceuticals Holding
7.5.1 Santhera Pharmaceuticals Holding Corporate Summary
7.5.2 Santhera Pharmaceuticals Holding Business Overview
7.5.3 Santhera Pharmaceuticals Holding Constrained Peptide Drugs Major Product Offerings
7.5.4 Santhera Pharmaceuticals Holding Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.5.5 Santhera Pharmaceuticals Holding Key News
7.6 Union Chimique Belge S.A. (UCB)
7.6.1 Union Chimique Belge S.A. (UCB) Corporate Summary
7.6.2 Union Chimique Belge S.A. (UCB) Business Overview
7.6.3 Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Major Product Offerings
7.6.4 Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.6.5 Union Chimique Belge S.A. (UCB) Key News
7.7 Pepscan Therapeutics B.V.
7.7.1 Pepscan Therapeutics B.V. Corporate Summary
7.7.2 Pepscan Therapeutics B.V. Business Overview
7.7.3 Pepscan Therapeutics B.V. Constrained Peptide Drugs Major Product Offerings
7.7.4 Pepscan Therapeutics B.V. Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.7.5 Pepscan Therapeutics B.V. Key News
7.8 Pepticom Ltd.
7.8.1 Pepticom Ltd. Corporate Summary
7.8.2 Pepticom Ltd. Business Overview
7.8.3 Pepticom Ltd. Constrained Peptide Drugs Major Product Offerings
7.8.4 Pepticom Ltd. Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.8.5 Pepticom Ltd. Key News
7.9 PeptiDream, Inc.
7.9.1 PeptiDream, Inc. Corporate Summary
7.9.2 PeptiDream, Inc. Business Overview
7.9.3 PeptiDream, Inc. Constrained Peptide Drugs Major Product Offerings
7.9.4 PeptiDream, Inc. Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.9.5 PeptiDream, Inc. Key News
7.10 CPC Scientific Inc.
7.10.1 CPC Scientific Inc. Corporate Summary
7.10.2 CPC Scientific Inc. Business Overview
7.10.3 CPC Scientific Inc. Constrained Peptide Drugs Major Product Offerings
7.10.4 CPC Scientific Inc. Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.10.5 CPC Scientific Inc. Key News
7.11 Creative Peptides
7.11.1 Creative Peptides Corporate Summary
7.11.2 Creative Peptides Business Overview
7.11.3 Creative Peptides Constrained Peptide Drugs Major Product Offerings
7.11.4 Creative Peptides Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.11.5 Creative Peptides Key News
7.12 Bio-Synthesis Inc
7.12.1 Bio-Synthesis Inc Corporate Summary
7.12.2 Bio-Synthesis Inc Business Overview
7.12.3 Bio-Synthesis Inc Constrained Peptide Drugs Major Product Offerings
7.12.4 Bio-Synthesis Inc Constrained Peptide Drugs Revenue in Global Market (2017-2022)
7.12.5 Bio-Synthesis Inc Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Constrained Peptide Drugs Market Opportunities & Trends in Global Market
Table 2. Constrained Peptide Drugs Market Drivers in Global Market
Table 3. Constrained Peptide Drugs Market Restraints in Global Market
Table 4. Key Players of Constrained Peptide Drugs in Global Market
Table 5. Top Constrained Peptide Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Constrained Peptide Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Constrained Peptide Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Constrained Peptide Drugs Product Type
Table 9. List of Global Tier 1 Constrained Peptide Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Constrained Peptide Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Constrained Peptide Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Constrained Peptide Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Constrained Peptide Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Constrained Peptide Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Constrained Peptide Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Constrained Peptide Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Constrained Peptide Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Constrained Peptide Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Constrained Peptide Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Constrained Peptide Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Constrained Peptide Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Constrained Peptide Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Constrained Peptide Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Constrained Peptide Drugs Revenue, (US$, Mn), 2023-2028
Table 30. Aileron Therapeutics, Inc Corporate Summary
Table 31. Aileron Therapeutics, Inc Constrained Peptide Drugs Product Offerings
Table 32. Aileron Therapeutics, Inc Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 33. Bicycle Therapeutics, PLC Corporate Summary
Table 34. Bicycle Therapeutics, PLC Constrained Peptide Drugs Product Offerings
Table 35. Bicycle Therapeutics, PLC Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Polyphor Limited Corporate Summary
Table 37. Polyphor Limited Constrained Peptide Drugs Product Offerings
Table 38. Polyphor Limited Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 39. Protagonist Therapeutics, Inc Corporate Summary
Table 40. Protagonist Therapeutics, Inc Constrained Peptide Drugs Product Offerings
Table 41. Protagonist Therapeutics, Inc Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Santhera Pharmaceuticals Holding Corporate Summary
Table 43. Santhera Pharmaceuticals Holding Constrained Peptide Drugs Product Offerings
Table 44. Santhera Pharmaceuticals Holding Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 45. Union Chimique Belge S.A. (UCB) Corporate Summary
Table 46. Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Product Offerings
Table 47. Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 48. Pepscan Therapeutics B.V. Corporate Summary
Table 49. Pepscan Therapeutics B.V. Constrained Peptide Drugs Product Offerings
Table 50. Pepscan Therapeutics B.V. Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Pepticom Ltd. Corporate Summary
Table 52. Pepticom Ltd. Constrained Peptide Drugs Product Offerings
Table 53. Pepticom Ltd. Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 54. PeptiDream, Inc. Corporate Summary
Table 55. PeptiDream, Inc. Constrained Peptide Drugs Product Offerings
Table 56. PeptiDream, Inc. Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 57. CPC Scientific Inc. Corporate Summary
Table 58. CPC Scientific Inc. Constrained Peptide Drugs Product Offerings
Table 59. CPC Scientific Inc. Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 60. Creative Peptides Corporate Summary
Table 61. Creative Peptides Constrained Peptide Drugs Product Offerings
Table 62. Creative Peptides Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
Table 63. Bio-Synthesis Inc Corporate Summary
Table 64. Bio-Synthesis Inc Constrained Peptide Drugs Product Offerings
Table 65. Bio-Synthesis Inc Constrained Peptide Drugs Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Constrained Peptide Drugs Segment by Type in 2021
Figure 2. Constrained Peptide Drugs Segment by Application in 2021
Figure 3. Global Constrained Peptide Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Constrained Peptide Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Constrained Peptide Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Constrained Peptide Drugs Revenue in 2021
Figure 8. By Type - Global Constrained Peptide Drugs Revenue Market Share, 2017-2028
Figure 9. By Application - Global Constrained Peptide Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Constrained Peptide Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Constrained Peptide Drugs Revenue Market Share, 2017-2028
Figure 12. US Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Constrained Peptide Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Constrained Peptide Drugs Revenue Market Share, 2017-2028
Figure 24. China Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Constrained Peptide Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Constrained Peptide Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Constrained Peptide Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. Aileron Therapeutics, Inc Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bicycle Therapeutics, PLC Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Polyphor Limited Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Protagonist Therapeutics, Inc Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Santhera Pharmaceuticals Holding Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Pepscan Therapeutics B.V. Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pepticom Ltd. Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. PeptiDream, Inc. Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. CPC Scientific Inc. Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Creative Peptides Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Bio-Synthesis Inc Constrained Peptide Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
